Evogene Ltd (EVGN)
$2.96
Performance
- $2.95$3.14$2.96
0.34%
Downside
Day's Volatility :5.98%
Upside
5.66%
- $2.91$10.40$2.96
1.69%
Downside
52 Weeks Volatility :72.02%
Upside
71.54%
Returns
| Period | Evogene Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | -57.4% | 0.0% |
6 Months | -69.16% | 0.0% |
1 Year | -60.53% | 0.0% |
3 Years | -90.75% | -22.3% |
Highlights
Market Capitalization | 17.1M |
Book Value | $0.6 |
Earnings Per Share (EPS) | 8.4 |
PE Ratio | 0.36 |
PEG Ratio | 0.0 |
Wall Street Target Price | 13.5 |
Profit Margin | -210.26% |
Operating Margin TTM | -667.62% |
Return On Assets TTM | -28.46% |
Return On Equity TTM | -82.37% |
Revenue TTM | 9.4M |
Revenue Per Share TTM | 1.88 |
Quarterly Revenue Growth YOY | 39.800000000000004% |
Gross Profit TTM | 766.0K |
EBITDA | -19.7M |
Diluted Eps TTM | 8.4 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.64 |
EPS Estimate Next Year | -3.46 |
EPS Estimate Current Quarter | -0.12 |
EPS Estimate Next Quarter | -0.08 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 356.08%
Technicals Summary
Sell
Neutral
Buy
Evogene Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Evogene Ltd | -30.35% | -69.16% | -60.53% | -90.75% | -82.49% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Evogene Ltd | 0.36 | 0.36 | 0.0 | -3.64 | -0.82 | -0.28 | NA | 0.6 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Evogene Ltd | Buy | $17.1M | -82.49% | 0.36 | -210.26% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Evogene Ltd
Decreasing Revenue
Revenue is down for the last 2 quarters, 4.19M → 914.0K (in $), with an average decrease of 78.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -3.86M → -5.41M (in $), with an average decrease of 40.3% per quarter
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 97.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 160.0%
Institutional Holdings
SILVERARC CAPITAL MANAGEMENT, LLC
5.75%Morgan Stanley - Brokerage Accounts
0.53%BNP Paribas Arbitrage, SA
0.17%LPL Financial Corp
0.12%UBS Group AG
0.12%Geode Capital Management, LLC
0.11%
Company Information
evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. the company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. in addition, evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. the company's headquarters are located in rehovot, israel and is listed for trading on the tel aviv stock exchange (tase: evgn) and on the new york stock exch
Organization | Evogene Ltd |
Employees | 142 |
CEO | Mr. Ofer Haviv CPA |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$2.96
-3.27%
Keyarch Acquisition Corp
$2.96
-3.27%
Connexa Sports Technologies Inc
$2.96
-3.27%
Us Value Etf
$2.96
-3.27%
First Wave Biopharma Inc
$2.96
-3.27%
Global X Msci Next Emerging
$2.96
-3.27%
Fat Projects Acquisition Corp
$2.96
-3.27%
Capital Link Global Fintech
$2.96
-3.27%
Applied Uv Inc
$2.96
-3.27%